Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Xencor, Inc.
Nuvectis Pharma, Inc.
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
A2 Biotherapeutics Inc.
University of Nebraska
Takeda
Kidney Cancer Research Bureau
Adela, Inc
Second Life Therapeutics
Elephas
Novartis
Kura Oncology, Inc.
Harvard Medical School (HMS and HSDM)
Elephas
Centre Hospitalier Universitaire de Besancon
AstraZeneca
Dana-Farber Cancer Institute
Coherus Oncology, Inc.
Virginia Commonwealth University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
University of Texas Southwestern Medical Center
7 Hills Pharma, LLC
A2 Biotherapeutics Inc.
Washington University School of Medicine
A2 Biotherapeutics Inc.
Genentech, Inc.
Institut Bergonié
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
DEKA Biosciences
Columbia University
Tempus AI
Arbeitsgemeinschaft medikamentoese Tumortherapie
Memorial Sloan Kettering Cancer Center
Elevation Oncology
Pfizer
Centre Georges Francois Leclerc
University Health Network, Toronto
Rutgers, The State University of New Jersey
Nimbus Therapeutics
Astellas Pharma Inc
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Inhibrx Biosciences, Inc
Hospices Civils de Lyon
Fondazione Policlinico Universitario Agostino Gemelli IRCCS